No significant differences inamputation rates were seen.6 A meta-analysis of theeffects of SGLT2 inhibitors on kidney outcomes across 13 largeplacebo-controlled trials found no association between SGLT2 inhibitors andlower-limb amputation when CANVAS/CANVAS-R was excluded (RR 1.06, 95% CI0.93-1.21; heterogeneity for CANVAS vs other 12 trials, P =.0007), and no association was found in an analysis specific to patientswith CKD and diabetes (RR 1.05, 95% CI 0.84-1.32).48 Nonetheless, goodfoot care is recommended in all patients with T2D.32 This evidence concerns the gene SLC5A2 and chronic kidney disease.